



LKT Laboratories, Inc.

Dacomitinib Anhydrous

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID D004098

CAS No. 1110813-31-4

Chemical Name

Synonym PF00299804 Anhydrous

Formula $C_{24}H_{25}ClFN_5O_2$

Formula Wt. 469.95

Melting Point


Purity $\geq 99\%$

Solubility

Store Temp $-20^{\circ}C$

Ship Temp Ambient

Description Dacomitinib is a selective and irreversible inhibitor of EGFR. Compared to first generation EGFR inhibitors, dacomitinib shows increased efficacy in models of non-small cell lung cancer (NSCLC) cells. It also suppresses proliferation of pancreatic ductal adenocarcinoma cells. TEST!!!!!!



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
D004098	5 mg	\$45.00
D004098	25 mg	\$98.00
D004098	100 mg	\$295.00

References Gonzales A., Hook K., Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. *Mol Cancer Ther.* 7(7):1880-9 (2008). PMID: 18606718.

Nagano T., Tachihara M., et al. Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer. *Drugs Today (Barc).* 55(4):231-236 (2019). PMID: 31050691.

Momeny M., Esmaili F., et al. The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells. *Cell Oncol.* 2019. PMID: 31025257.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.